Benson Fong

Chief Financial Officer

Mr. Fong brings more than three decades of senior financial leadership and corporate development experience. Mr. Fong is the Managing Director of Nehalem Advisory, LLC guiding several life science startups with their financial strategy and implementation. He also collaborates with Potrero Hill Advisors. Before joining Nehalem Advisory, he was consulting CFO and Account Director at Engine Room and CFO at Early Growth Financial Services. Previously, he served as President and CEO of Lapis Therapeutics as well as Senior VP Corporate Development at CoTherix where he was responsible for in-licensing Ventavis® (iloprost) which was later FDA approved and successfully launched.

Prior experience included serving as the first VP for venture debt lending at Imperial Bank/Comerica, CFO at Cibus Pharmaceutical, Controller at Matrix Pharmaceuticals, and Division Controller in Express Banking at Wells Fargo Bank. Mr. Fong started his career as a senior tax accountant and CPA at Arthur Young & Co. Mr. Fong has a successful track record in negotiation including licensing agreements, R&D sponsored research, manufacturing and lease agreements. His leadership responsibilities have included filing S-1s, equity and debt financing, and product licensing.  Mr. Fong received a B.S. in Biology from the University of Oregon.